310 related articles for article (PubMed ID: 34258797)
21. Hemostatic Alterations in Patients With Cirrhosis: From Primary Hemostasis to Fibrinolysis.
Zermatten MG; Fraga M; Moradpour D; Bertaggia Calderara D; Aliotta A; Stirnimann G; De Gottardi A; Alberio L
Hepatology; 2020 Jun; 71(6):2135-2148. PubMed ID: 32090357
[TBL] [Abstract][Full Text] [Related]
22. Controversies in anticoagulation therapy in patients with cirrhosis.
Sasso R; Rockey DC
Curr Opin Gastroenterol; 2019 May; 35(3):161-167. PubMed ID: 30844894
[TBL] [Abstract][Full Text] [Related]
23. Critical issues in hematology: anemia, thrombocytopenia, coagulopathy, and blood product transfusions in critically ill patients.
Drews RE
Clin Chest Med; 2003 Dec; 24(4):607-22. PubMed ID: 14710693
[TBL] [Abstract][Full Text] [Related]
24. The prothrombotic activity of cancer cells in the circulation.
Mitrugno A; Tormoen GW; Kuhn P; McCarty OJ
Blood Rev; 2016 Jan; 30(1):11-9. PubMed ID: 26219246
[TBL] [Abstract][Full Text] [Related]
25. [The disorders of hemostasis and their prevention with low-molecular heparins in oncological patients].
Somonova OV; Kushlinskiĭ NE
Klin Lab Diagn; 2014 Jul; 59(7):21-4. PubMed ID: 25346984
[TBL] [Abstract][Full Text] [Related]
26. In vitro efficacy of pro- and anticoagulant strategies in compensated and acutely ill patients with cirrhosis.
Lisman T; Kleiss S; Patel VC; Fisher C; Adelmeijer J; Bos S; Singanayagam A; Stoy SH; Shawcross DL; Bernal W
Liver Int; 2018 Nov; 38(11):1988-1996. PubMed ID: 29768734
[TBL] [Abstract][Full Text] [Related]
27. Management of Coagulation and Anticoagulation in Liver Transplantation Candidates.
Northup P; Reutemann B
Liver Transpl; 2018 Aug; 24(8):1119-1132. PubMed ID: 30142249
[TBL] [Abstract][Full Text] [Related]
28. Coagulation, hemostasis, and transfusion during liver transplantation.
Thai C; Oben C; Wagener G
Best Pract Res Clin Anaesthesiol; 2020 Mar; 34(1):79-87. PubMed ID: 32334789
[TBL] [Abstract][Full Text] [Related]
29. Device-induced platelet dysfunction in mechanically assisted circulation increases the risks of thrombosis and bleeding.
Chen Z; Zhang J; Kareem K; Tran D; Conway RG; Arias K; Griffith BP; Wu ZJ
Artif Organs; 2019 Aug; 43(8):745-755. PubMed ID: 30805954
[TBL] [Abstract][Full Text] [Related]
30. Next-generation antithrombotics in ischemic stroke: preclinical perspective on 'bleeding-free antithrombosis'.
Kraft P; De Meyer SF; Kleinschnitz C
J Cereb Blood Flow Metab; 2012 Oct; 32(10):1831-40. PubMed ID: 22805877
[TBL] [Abstract][Full Text] [Related]
31. Cirrhotic coagulopathy: A rebalanced hemostasis.
Singh AD; Mucha SR; Lindenmeyer CC
Cleve Clin J Med; 2022 Sep; 89(9):523-533. PubMed ID: 37907441
[TBL] [Abstract][Full Text] [Related]
32. Anticoagulation in Patients With Cirrhosis: Caught Between a Rock-Liver and a Hard Place.
Ha NB; Regal RE
Ann Pharmacother; 2016 May; 50(5):402-9. PubMed ID: 26861989
[TBL] [Abstract][Full Text] [Related]
33. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity.
Lisman T; Bongers TN; Adelmeijer J; Janssen HL; de Maat MP; de Groot PG; Leebeek FW
Hepatology; 2006 Jul; 44(1):53-61. PubMed ID: 16799972
[TBL] [Abstract][Full Text] [Related]
34. Major Changes of von Willebrand Factor Multimer Distribution in Cirrhotic Patients with Stable Disease or Acute Decompensation.
Palyu E; Harsfalvi J; Tornai T; Papp M; Udvardy M; Szekeres-Csiki K; Pataki L; Vanhoorelbeke K; Feys HB; Deckmyn H; Tornai I
Thromb Haemost; 2018 Aug; 118(8):1397-1408. PubMed ID: 29972862
[TBL] [Abstract][Full Text] [Related]
35. New targets for antithrombotic drugs.
Thiagarajan P
Am J Cardiovasc Drugs; 2002; 2(4):227-35. PubMed ID: 14727968
[TBL] [Abstract][Full Text] [Related]
36. Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis.
Senzolo M; M Sartori T; Rossetto V; Burra P; Cillo U; Boccagni P; Gasparini D; Miotto D; Simioni P; Tsochatzis E; A Burroughs K
Liver Int; 2012 Jul; 32(6):919-27. PubMed ID: 22435854
[TBL] [Abstract][Full Text] [Related]
37. Established and new-generation antithrombotic drugs in patients with cirrhosis - possibilities and caveats.
Lisman T; Kamphuisen PW; Northup PG; Porte RJ
J Hepatol; 2013 Aug; 59(2):358-66. PubMed ID: 23548197
[TBL] [Abstract][Full Text] [Related]
38. The Interface between Immunotransfusion and Hemostasis and Thrombosis Testing.
Franchini M
Methods Mol Biol; 2017; 1646():43-56. PubMed ID: 28804817
[TBL] [Abstract][Full Text] [Related]
39. The evolving knowledge on primary hemostasis in patients with cirrhosis: A comprehensive review.
Zanetto A; Campello E; Senzolo M; Simioni P
Hepatology; 2024 Feb; 79(2):460-481. PubMed ID: 36825598
[TBL] [Abstract][Full Text] [Related]
40. Preserved clot formation detected by the Thrombodynamics analyzer in patients with cirrhosis.
Potze W; Adelmeijer J; Porte RJ; Lisman T
Thromb Res; 2015 May; 135(5):1012-6. PubMed ID: 25746364
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
